Clinical assessment of gene therapies for hemophilia A and hemophilia B: Key takeaways for your practice
This program is supported by CSL Behring
3:00 p.m. - 6:00 p.m. Pacific time
ACCESS PROGRAM HERE
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 8-9
On Demand program will be available here December 21, 2024.
Access Program Here
Join us live and in person for an exciting discussion on assessing gene therapies for hemophilia A and hemophilia B. Hematologists, emergency medicine physicians, nurses, nurse practitioners, physician assistants, and other members of the hemophilia care team will benefit from this interactive and nuanced discussion by an expert panel on the clinical and practical evidence surrounding gene therapies for hemophilia, the differences in gene therapies for hemophilia A and hemophilia B, how to identify eligible candidates for gene therapies for hemophilia A and B, monitor patients with hemophilia who receive gene therapies, and how to counsel patients and colleagues about gene therapies for hemophilia A and B.
Speakers:
Amy Dunn, MD
Nationwide Children's Hospital
Columbus, OH
Steven W. Pipe, MD
University of Michigan
Ann Arbor, MI
Doris V. Quon, MD, PhD
Orthopaedic Hospital
Los Angeles, CA
Vikki Chavis
, Medscape
Email: vchavis@medscapelive.com